Beyond The Stigma: Psychedelics in The Fight Against Depression and PTSD
Avrina Kartika Ririe, Ellen Y. Huang, Lubna M Syed, FNU Sagar, Hrishik Iqbal
Journal of Carcinogenesis 2025 DOI: 10.64149/j.carcinog.24.5s.529-535 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey study Longitudinal Peer reviewed |
|---|---|
| Population | People with depression and/or PTSD who had prior experience using psychedelics, selected via stratified random sampling |
| Interventions | Psilocybin MDMA |
| Topics | Depression PTSD |
| Key findings | Respondents with a history of psychedelic use reported better improvements in depression and PTSD symptoms than others, with MDMA reported as most helpful for PTSD and psilocybin for depression. The author argues that "patient control" alongside supportive therapeutic frameworks under therapist guidance was crucial to psychotherapy success, and concludes psychedelics may help people who have not found relief through other treatments, while calling for longitudinal research on safety and sustained benefits. |
Abstract
Background: Mental health issues, most notably depression and post-traumatic stress disorder (PTSD) continue to be prevalent and challenging to address through conventional approaches. While some PTSD patients obtain relief from medication and psychotherapy, many others still contend with persistent symptoms and residual impacts. Nevertheless, the shifting perspectives and attention being devoted to overlooked compounds like psilocybin and MDMA call for more research into the therapeutic potential of psychedelics.
Objective: This study looked into the treatment effects of psychedelics on depression and PTSD symptoms, as well as the underlying brain mechanisms associated with symptom relief and treatment response.
Methods: The author undertook a structured cross-sectional study, collecting data on the usage of psychedelics and their self-reported efficacy in treating depression and PTSD through administered surveys. Depression and/or PTSD patients who had prior experience with psychedelics were chosen via stratified random sampling. The survey included questions concerning the respondents' mental health history, usage of psychedelics, and their effectiveness in treating depression and/or PTSD. The author evaluated the effect of psychedelics on the mental health of the patients using descriptive statistics, paired t-tests, and regression analysis.
Results: The study showed that users with a history of using psychedelics reported better improvements in their depression and PTSD symptoms than others. MDMA helped decrease PTSD the most, while psilocybin eased depression the most. The study also noted the positive impact psychedelics have on emotional self-processing, self-reflection, tissue damage, self-repair, and neuroplastic change. In addition, the data suggested that the use of 'patient control' alongside helpful therapeutic frameworks under the appropriate direction of the therapist was crucial for the success of psychotherapy using psychedelics.
Conclusions: There is a growing body of evidence that indicates that psychedelics can be an effective treatment for depression and PTSD in people who have not found relief through other treatments. The therapeutic effects stem from the changeable structural and functional connections of the patient's brain induced by psychedelics that lead to better control over emotions. Despite their promise, these treatments need further study, including longitudinal research on their safety, efficacy, and sustained benefits. In addition, the ethical aspects of the use of psychedelics in therapy need to be addressed, particularly about the patient's protection, informed consent, and legal limitations.